Study On The Efficiency And Potential Of China’s Medical Products Export Trade To RCEP Member Countries

The medical industry is an important part of safeguarding people’s livelihood and promoting national economic and trade development,and the entry into force of the Regional Comprehensive Economic Partnership Agreement(RCEP)has elevated the trade liberalization of medical products to a new level.Firstly,based on the facts of China’s medical products export trade characteristics to RCEP member countries,the export competitiveness of Chinese medical products in the RCEP regional market and the opportunities and challenges faced by China’s medical products exports in RCEP member countries are analyzed to qualitatively study the export level.Secondly,based on the time-varying stochastic frontier gravity model,China’s export trade volume of medical products to RCEP member countries from 2003 to 2020 is combined to analyze the main factors affecting the export trade efficiency,measure the trade efficiency and potential,and classify the countries with different trade efficiency and potential based on the Boston matrix method.The results show that in recent years,China’s exports of medical products in the RCEP market are generally expanding,export efficiency is increasing over time,and there are obvious differences in trade potentials of different countries.Among them,personal protective products have a strong export competitive advantage,and Japan and ten ASEAN countries are the core markets for China’s medical products exports to RCEP member countries.The empirical analysis finds that the difference in GDP per capita between China and the host country,the population size of the host country,the degree of population aging,political stability,economic freedom,and logistics performance are conducive to trade efficiency improvement,and the level of general health expenditure of the host government has a significant hindering effect on trade efficiency improvement.To this end,the following suggestions are made: follow the comparative advantages of medical products and gradually promote product restructuring;align with international standards externally and strengthen regulation internally;and create a differentiated cooperation model according to local conditions.